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Vasoplegic syndromeAbstract Background and aim: Vasoplegic syndrome (VS) is a frequent complication following
cardiopulmonary bypass (CPB) requiring escalating dose of vasopressor support. The guanylate
cyclase inhibitor methylene blue (MB) could be an attractive alternative treatment in such cases.
This study examines the efficacy and safety of using MB compared to the commonly used nore-
pinephrine in VS in pediatric population following CPB.
Methods: Forty patients of pediatric age group who developed VS following CPB for elective cor-
rective cardiac surgeries received 0.5 lg/kg/min norepinephrine intravenous infusion for 5 min with-
out improvement (Time 1). Patients were randomly assigned to two equal groups. Group MB
received 1.5 mg/kg methylene blue by intravenous infusion over 20 min. Group N did not receive
MB. Norepinephrine infusion was continued in both groups and titrated according to the response
of patients with a maximum dose of 2 lg/kg/min (Time 2). Heart rate, mean arterial pressure
(MAP), central venous pressure (CVP), cardiac output (CO), cardiac index (CI), mean pulmonary
artery pressure (MPAP), systemic vascular resistance (SVR) and systemic vascular resistance index
(SVRI) were calculated in both groups. Side effects related to the study drug were recorded.
Results: Time 2 values of norepinephrine dose were significantly lower in MB group compared to
N group. Time 2 values of MAP were significantly higher in MB group compared to N group with a
significant decrease in HR in MB group compared to N group. No change in the rhythm was
detected in the two groups. Time 2 values of CVP were higher in MB group compared to N group.
Time 2 values of CO and CI were significantly lower in MB group compared to N group and SVR
and SVRI were significantly higher in MB group compared to N group. Time 2 values of MPAP
were comparable in both groups and showed no significant change. No side effects from using
MB were recorded as pulmonary edema and respiratory distress.
270 R. Abdelazim et al.Conclusion: In this study, MB showed superior efficacy and safety in managing VS in pediatrics
following CPB compared to the conventionally used norepinephrine.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiopulmonary bypass (CPB) may be complicated by persis-
tent hypotension due to low systemic vascular resistance, in 5–
22% of patients [1,2]. Different causes have been associated
with this situation, such as hypothermia, duration of CPB,
total cardioplegic volume infused, reduced left ventricular
function, preoperative treatment with angiotensin-converting
enzyme inhibitors, and systemic inflammatory response syn-
drome (SIRS), or inappropriate low arginine-vasopressin
secretion. An advanced form of this hypotension is the vaso-
plegic shock which is a life-threatening condition, intractable
in the usual management with fluid administration, inotropes,
and even vasopressor catecholamines [3,4].
Vasoplegic syndrome (VS) is generally defined as a mean
arterial pressure (MAP) <50 mmHg, cardiac index (CI)
>2.5 L/min/m2, right atrial pressure <5 mmHg, left atrial
pressure <10 mmHg and low systemic vascular resistance
(SVR) <800 dyne s/cm5 [5].
Although largely effective in reestablishing minimally accept-
able mean arterial pressures to maintain organ perfusion, cate-
cholamines have important adverse effects and may even
increase mortality rates. For example, norepinephrine, a potent
and commonly used a-adrenergic agent in cases of septic shock,
may decrease cardiac output (CO), oxygen delivery, and blood
flow tovulnerable organsdespite adequateperfusionpressure [6].
Methylene blue (MB) or tetramethylthionine chloride is a
well described alternative treatment for VS. It is believed to
interfere with the nitric oxide (NO)-cyclic guanylate
monophosphate (cGMP) pathway, inhibiting its vasorelaxant
effect on smooth muscle. Methylene blue (MB) has been used
to treat refractory hypotension in anaphylaxis, septic shock
and after CPB in adults [7–9]. Methylene blue has been used
in pediatrics in several limited trials to treat septic shock [10]
and methemoglobinemia [11].
In this prospective randomized controlled trial, methylene
blue is compared to norepinephrine use in pediatric patients
who developed vasoplegic syndrome after CPB.2. Patients and methods
After approval of local ethics committee and informed written
consent from patients’ parents, this randomized trial was done
between March 2013 and April 2015. The study included forty
patients between the age of 2 and 8 years old who developed
systemic vasoplegic syndrome out of 1500 various elective
pediatric corrective cardiac surgeries performed with CPB sup-
port at Atfal Misr Hospital.
Inclusion criteria were all patients who were diagnosed with
vasoplegia after cardiopulmonary bypass. Vasoplegia was
diagnosed by the following criteria: mean arterial pressure
650 mmHg, systemic vascular resistance (SVR) <800 dyn s/cm5
or systemic vascular resistance index (SVRI) 61500 dyn s/cm5/m2,cardiac index (CI) P2.5 L/min/m2 and all patients received
intravenous norepinephrine infusion of 0.5 lg/kg/min for
5 min without improvement (Time 1).
We assigned patients randomly into 2 groups by using a
computer-generated random-number sequence and sealed
envelopes; Group MB: 20 patients received the guanylate
cyclase inhibitor MB (METHYLENE BLUE INJECTION,
USP 1%, AMERICAN REGENT, INC.) in a dose of
1.5 mg/kg by intravenous infusion over 20 min in addition to
norepinephrine infusion, the rate of which was adjusted for
restoration of mean systemic blood pressure and SVRI (Time
2). Group N: 20 patients received norepinephrine intravenous
infusion titrated according to the response of patients (Time
2). The maximum dose of norepinephrine was 2 lg/kg/min in
both groups.
Exclusion criteria were previous cardiac surgery, metabolic,
renal or hepatic disorders, ejection fraction (EF) lower than
0.50, with mean pulmonary arterial pressure (MPAP) more
than 15 mmHg [both were determined by echocardiography],
and patients with history of glucose-6-phosphate dehydroge-
nase (G6PD) deficiency. Also patients with abnormal valve
area and patients with more than mild aortic or mitral regurge
were excluded due to (echo) measurement difficulties. Patients
not responding to the maximum norepinephrine dose of
2 lg/kg/min were excluded from the study and replaced by
equal number of patients fulfilling the inclusion criteria.
Children were given 0.5 mg/kg of midazolam half an hour
before induction of anesthesia as oral premedication. Anesthe-
sia was induced by intravenous (IV) midazolam (0.05 mg/kg),
propofol (1 mg/kg) and fentanyl (10 lg/kg). Anesthesia was
maintained by inhalational isoflurane 0.5% supplemented with
fentanyl increments of 1 lg/kg. Pancuronium bromide was
used for neuromuscular blockade. Ventilation was pressure
controlled (to ensure normal blood gases). Anticoagulation
was accomplished with 400 IU/kg of heparin and further doses
were added as required to maintain an activated clotting time
longer than 400 s.
All CPB was primed by colloids and carried out at non-
pulsatile, filtered arterial pump flow 2.5–3.0 L/min/m2 and
gravity venous drainage. A hollow-fiber membrane oxygenator
was used. Initial ante-grade warm hyperkalemic blood cardio-
plegia (20 ml/kg) was used and (10 ml/kg) was repeated every
25 min. The hematocrit was kept at 25% and the pH was man-
aged by alpha-state strategy. Mean arterial pressure (MAP)
was kept between 30 and 50 mmHg. Patients were cooled
down to 28–30 C. Nitroglycerin infusion (1–3 lg/kg/min)
was started during CPB and titrated according to need. Once
CPB re-warming was started, norepinephrine infusion (0.05–
0.5 lg/kg/min) was added according to the hemodynamic
parameters. Hypertension and hypotension were defined as
an increase or a decrease in Mean Arterial Pressure (MAP)
by P20% from baseline, respectively. Hypertension was trea-
ted with increments of fentanyl. Hypotension was treated by
intravenous administration of lactated Ringer’s solution
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was one-third of the aortic cross-clamping time. After wean-
ing, the remaining blood volume of the CPB circuit was
retransfused until the end of the operation. Heparin effects
were reversed by protamine at a 1:1 ratio.
EF and MPAP were determined using trans-esophageal
echocardiography. Left ventricular ejection fraction and
MPAP were defined as normal when more than 0.50 and
within 12–15 mmHg respectively.
For all patients, demographic data, past medical and drug
history, pre-operative EF, type of surgical intervention, num-
ber of doses and total dose of cardioplegia, the aortic cross-
clamp, and CPB times were recorded. The direct invasive
MAP, central venous pressure (CVP), heart rate (HR), pulse
oximetry (SpO2), end tidal CO2, and electrocardiogram were
monitored continuously.
CO, CI, SVR and SVRI were assessed after CPB and one
hour after finishing infusion of MB using trans-esophageal
echo and calculation. The total dose of norepinephrine was
recorded in each group. For all cases, the pre-operative diam-
eter of aortic valve annulus (mm), aortic valve area (cm2), and
aortic valve area index (cm2/m2) were recorded.
Calculation of SVR was carried out through measurement
of time velocity integral (TVI) on the LVOT in the deep
trans-gastric four chamber view using pulsed wave Doppler
(PWD). This was achieved through adoption of the following
equations:
Resistance ¼ pressure gradient = Cardiac outputðCOÞ:
Cardiac outputðCOÞ ¼ TVIAVAHR
where TVI is the time velocity integral that represents distance
of the RBC crossed in a single heart beat.
AVA is aortic valve area through which blood flows to sys-
temic circulation.
Assuming that LVOT is a cylinder so blood volume ejected
in a single heart beat will equal the volume of a cylin-
der = Base area  height or AVA  TVI = Stroke volume
(SV)
Stroke volumeðSVÞ HR ¼ CO
This method has been clinically validated by Abbas and his
colleagues [12] who conducted that ‘‘Doppler echocardiogra-
phy provides a reliable non invasive assessment of SVR”.
Pressure gradient is the difference between mean arterial
blood pressure and central venous pressure MAP–CVP.
 So final equation will be SVR ¼ 80 ðMAP–CVP=TVI
AVAHRÞ.
Systemic vascular resistance index will be calculated as
follows
SVRI ¼ SVR=body surface area
Normal values:
 Stroke volume index 40–85 mL/m2/beat.
 Systemic vascular resistance index 1970–2390 dynes s/cm5/m2.
 Systemic vascular resistance 900–1600 dynes s/cm5.
 Normal value of TVI LVOT 16 ± 3 cm.
 Normal value of TVI aortic valve 22 ± 4 cm.
 Aortic valve area index 1.33 cm2/m2.3. Sample size
A sample size of 18 patients per group achieves 83% power to
detect a mean of paired differences of 300.0 in SVR with an
estimated standard deviation of differences of 200.0 and with
a significance level (alpha) of 0.05 using a two-sided paired
t-test. We included 20 patients in each group for possible
dropouts.
3.1. Statistical analysis
The statistical analysis was performed using a standard SPSS
software package version 17 (Chicago, IL). Normally dis-
tributed numerical data are presented as mean ± SD and dif-
ferences between groups were compared using the independent
Student’s t-test, and categorical variables were analyzed using
the v2 test or Fisher’s exact test as appropriate and are pre-
sented as number (%). p-value < 0.05 is considered statisti-
cally significant.4. Results
There were no significant differences in patients’ characteristics
between the two groups (Table 1). Cardiopulmonary bypass
details showed no significant differences between the two
groups (Table 2).
Norepinephrine dose in (Time 2) was significantly
decreased in MB group and significantly increased in N group
compared to pre-infusion (Time 1) values in each group. Post-
infusion (Time 2) norepinephrine dose was significantly lower
in MB group compared to N group (Table 3).
The Time 1 values of heart rate, MAP and CVP showed no
significant differences between the two groups (Table 3). The
MAP increased significantly in Time 2 compared to Time 1
in MB group while there was no significant increase in Time
2 compared to Time 1 in N group. The Time 2 MAP was sig-
nificantly higher in MB group compared to N group. The HR
decreased significantly in Time 2 compared to Time 1 in MB
group while it showed no significant change in Time 2 com-
pared to Time 1 in N group. This was accompanied with sig-
nificant decrease in HR in MB group when compared to N
group. No change was detected in the rhythm in the two
groups (none of the patients showed major or prolonged dys-
rhythmia which needed defibrillation or pacing). In addition
there was significant increase in CVP in Time 2 compared to
Time 1 in MB group while N group showed no change in Time
2 compared to Time 1, and also in Time 2 CVP was higher in
MB group compared to N group (Table 3).
The Time 1 values of CO, CI, MPAP, SVR and SVRI
showed no significant differences between the two groups
(Table 4). There was a significant decrease in CO and CI and
significant increase in SVR and SVRI in Time 2 compared to
Time 1 in MB group while in N group, there was no significant
change comparing Time 2 to Time 1 in CO, CI, SVR and
SVRI. Time 2 values of CO and CI were significantly lower
in MB group compared to N group and SVR and SVRI were
significantly higher in MB group compared to N group. Time 2
values of MPAP did not show significant change compared to
Time 1 values in both groups. Time 2 values of MPAP were
comparable in both groups (Table 4).
Table 1 Patients’ Characteristics.
Variable MB group (n= 20) N group (n= 20) p-value
Age (months) 30.85 ± 10.12 31.4 ± 7.7 0.85
Weight (kg) 12.14 ± 1.23 12.3 ± 1.37 0.78
Height (cm) 90.65 ± 6.7 91.1 ± 5.9 0.46
BSA (m2) 0.55 ± 0.12 0.56 ± 0.31 0.936
Sex (male/female) 13/7 11/9 0.747
Diagnosis
– AV 7 8 0.892
– VSD 8 7
– VSD+ ASD 1 2
– F4 4 3
Down 5 7 0.9
Preoperative ACEI 15 15 1
Preoperative diuretic 16 13 0.479
Preoperative beta- blocker 6 7 0.736
Doses of cardioplegia
– 2 doses 16 15 0.705
– 3 doses 4 5
Preoperative hematocrit (%) 43.6 ± 5 41.2 ± 4.7 0.135
Diameter of aortic valve annulus (mm) 9.05 ± 0.77 9.045 ± 0.73 0.983
Aortic valve area (cm2) 0.76 ± 0.06 0.765 ± 0.078 0.673
Aortic valve area index (cm2/m2) 1.27 ± 0.103 1.24 ± 0.85 0.329
Preoperative EF (%) 0.577 ± 0.11 0.587 ± 0.1 0.74
Values are presented as mean ± SD or number. BSA: body surface area, AV: common atrio-ventricular canal, VSD: ventricular septal defect,
ASD: atrial septal defect, F4: Fallot’s tetralogy, ACEI: angiotensin converting enzyme inhibitor.
All p-values are >0.05, insignificant difference.
Table 2 Cardiopulmonary bypass details.
Variable MB group (n= 20) N group (n= 20) p-value
Temperature on CPB (C) 27.15 ± 1.05 27 ± 1.35 0.691
Volume of cardioplegic solution (ml) 329.7 ± 109 351.5 ± 90.97 0.230
Duration of CPB (min) 95.3 ± 5.4 93.05 ± 4.96 0.177
Duration of AoX (min) 69.3 ± 8.3 67.55 ± 8.3 0.51
SaO2 (%) 97.75 ± 0.9 98.1 ± 0.89 0.298
Dose of nitroglycerin (lg/kg/min) 1.97 ± 0.37 2.06 ± 0.4 0.448
Values are presented as mean ± SD. CPB: cardiopulmonary bypass, AoX: aortic cross clamping.
All p-values are >0.05, insignificant difference.
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98.6 ± 0.6% for MB group and 98.8 ± 0.7% for N group
with no significant difference between both groups (p-value
0.875). All the 20 cases in MB group showed change of the
color of urine to greenish blue. No side effects from using
MB were recorded as arrhythmia, respiratory distress, and pul-
monary edema (see Fig. 1).5. Discussion
In this prospective randomized controlled study, methylene
blue significantly increased MAP, CVP, SVR, and SVRI while
this effect was not observed in norepinephrine group. MB also
decreased the dose requirements of norepinephrine used with
no recorded side effects (except bluish discoloration of urine)
thus improving the outcome in pediatric patients suffering
from vasoplegic syndrome following CPB.Vasoplegic syndrome is a state of endothelial dysregulation
resulting in persistent hypotension and low systemic vascular
resistance despite adequate fluid resuscitation and vasopressor
administration [13]. It is a form of severe systemic inflamma-
tory response syndrome (SIRS) that occurs during the early
postoperative period after cardiac surgery with cardiopul-
monary bypass [4] due to generation of pro-inflammatory
mediators secondary to surgical stress, hypothermia, neutral-
ization of heparin with protamine, the transfusion of blood
products or occurrence of endotoxemia due to repeated epi-
sodes of hypotension from displacement and mobilization of
the heart [14]. Additional factors to the development of VS
include preoperative chronic heart failure with low EF less
than 35%, preoperative use of angiotensin converting enzyme
inhibitors, Beta blockers, pre- and post-operative use of amio-
darone and phosphodiesterase inhibitors [milrinone] [15,16].
It is reported that SIRS occurring after cardiac surgery is
associated with a massive, unbalanced induction of
Table 3 Comparison between Time 1 and Time 2 values of the studied drugs in heart rate, MAP and CVP.
MB group (n= 20) N group (n= 20) p-value (Time 1 MB versus N) p-value (Time 2 MB versus N)
Time 1 Time 2 Time 1 Time 2
Norepinephrine
(lg/kg/min)
0.5 ± 0 0.11 ± 0.019 0.5 ± 0 1.42 ± 0.5 1 <0.001**
<0.001* <0.001*
Heart rate
(beat/m)
165.6 ± 5.8 151.75 ± 4.57 165.8 ± 6.6 161 ± 3.7 0.919 <0.001**
<0.001* 0.82
MAP (mmHg) 39.1 ± 4.5 56 ± 4.6 38.5 ± 5 43.5 ± 10.6 0.692 <0.001**
<0.001* 0.085
CVP (mmHg) 4.95 ± 0.69 7.2 ± 0.7 4.9 ± 2.83 5.9 ± 2.3 0.939 <0.001**
<0.001* 0.335
MAP: mean arterial blood pressure, CVP: central venous pressure.
Values are presented as mean ± SD. p-value <0.05 significant difference.
* Statistically significant between Time1 and Time 2 values in each group.
** Statistically significant between the two groups.
Table 4 Comparison between Time 1 and Time 2 values of the studied drugs in CO, CI, MPAP, SVR and SVRI.
MB Group (n= 20) N Group (n= 20) p-value (Time 1 MB
versus N)
p-value (Time 2 MB
versus N)
Time 1 Time 2 Time 1 Time 2
CO (l/min) 3.83 ± 0.43 3.3 ± 0.22 3.72 ± 0.51 3.51 ± 0.18 0.465 0.002**
<0.001* 0.09
CI (l/min/m2) 6.96 ± 0.46 6.0 ± 0.3 6.64 ± 0.82 6.27 ± 0.38 0.136 0.017**
<0.001* 0.075
MPAP (mmHg) 22.25 ± 3.1 23.95 ± 2.3 22.55 ± 3.71 23.85 ± 2.37 0.783 0.890
0.056 0.195
SVR (dyn s/cm5) 675.37 ± 40 1219.39
± 121.6
696.66
± 78.65
721.57 ± 97.3 0.287 <0.001**
<0.001* 0.379
SVRI (dyn s/cm5/
m2)
1227.94
± 155.29
2217.07
± 143.1
1242.85
± 170.2
1287.44
± 230.87
0.774 <0.001**
<0.001* 0.491
CO: cardiac output, CI: cardiac index, MPAP: mean pulmonary artery pressure, SVR: systemic vascular resistance, SVRI: systemic vascular
resistance index.
Values are presented as mean ± SD. p-value <0.05 significant difference.
* Statistically significant between Time 1 and Time 2 values in each group.
** Statistically significant between the two groups.
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inducible form of nitric oxide (NO) synthase [18]. NO in turn
stimulates the production of cGMP. Excessive formation of
NO and cGMP is related to profound vasodilatation, myocar-
dial depression, and decreased response to catecholamines [7].
Methylene blue antagonizes the effect of NO and other nitrova-
sodilators in the endothelium and vascular smooth muscle by
acting competitively with NO, binding to iron heme-moiety of
soluble guanylylcyclase (sGC) and blocking sGC action in vas-
cular smoothmuscle [19]. Regarding recovery and better control
of blood pressure, it must be made clear that MB alone is not a
vasoconstrictor. By blocking the cGMP, it ‘‘releases” the cAMP
system in a kind of ‘‘crosstalk” between the two systems, and
thus, norepinephrine exercises its vasoconstrictor effect [20].
MB has chiefly been used to treat patients with septic shock
and low peripheral vascular resistance [21,22].
In the present study, MB group showed a significant
increase in MAP, CVP, SVR, and SVRI accompanied with a
significant decrease in CO, CI and HR but with no arrhythmia
detected which indicated an improvement in the signs of VS.This is consistent with a study done by Leyh et al. [23] who
used MB in a single dose (2 mg/kg) after CPB and recorded
an increase in MAP, a decrease in the dose of norepinephrine,
a significant decrease in CO and a decrease in the serum lactate
within 24 h in the MB group.
Another studywas done byLevin et al. [24] who usedMB in a
dose of 1.5 mg/ kg over 1 h to treat VS after CPB and found that
VS resolved completely inMB group with lower mortality com-
pared to the control group. Also Maslow et al. [25] used MB
after CPB in patients who received ACEI in a dose of 3 mg/kg
and recorded an increase in theMAP and SVR, decreased nore-
pinephrine requirements and decreased serum lactate.
Regarding ethical aspects, it can be affirmed that MB can
be used in clinical practice because it has been used since late
19th century for the treatment of malaria, which granted Paul
Ehrlich the Medicine Nobel Prize in 1908. MB is the precur-
sory molecule of the following: chemotherapy, antibiotics
and neuroleptics (chlorpromazine), with long use as an urinary
antiseptic, Schizophrenia treatment was an additive to stored
blood bags, in order to neutralize microorganisms [20].
Assessed for eligibility (n = 46)
Excluded (n=6)
-Did not meet inclusion criteria (n=6)
-Parents' declined to participate (n=0)
All paents received 
norepinephrine 0.5 μg/kg/min for 
5 minutes without response.
40 paents randomized
Allocated to norepinephrine group N     
(n= 20)
• Received allocated intervenon 
(n=20).
Allocated to methylene blue group MB     
(n= 20)
• Received allocated intervenon 
(n=20).
Disconnued intervenon (n=0)
Lost to follow –up (n= 2) due to death
Disconnued intervenon (n=0)
Lost to follow –up (n= 1) due to death
Replaced by 
another 2 
paents
Analyzed (n=20) Analyzed (n=20)
Enrolment
Allocaon 
Follow-up
Analysis
Replaced by 
another 
paent 
Figure 1 Study flowchart.
274 R. Abdelazim et al.In the current study, no statistically significant change was
observed in MPAP as expected in the MB group (the same
observation was recorded in the norepinephrine group); this
is mainly attributed to the small dose of MB used. Several
studies stated that unlike in the systemic circulation, MB
induced dose-dependent increases in pulmonary arterial pres-
sure and vascular resistance [26,27].
The current study is one of few studies that discussed the
probability of using MB in pediatrics. There is no dose regimen
for MB in children but using it in a dose less than 2 mg/kg
appears to be safe (lethal dose is 40 mg/kg) [28]. Thus the
MB dose in this study was chosen to be 1.5 mg/kg. No side
effects were observed other than change in the color of urine.
MB was used in other studies on pediatric patients to treat
refractory hypotension due to sepsis [10,29] and methe-
moglobinemia [11,30]. Another study used MB in a dose of1 mg/kg on a 5 years old girl with hypoplastic left ventricle
with a failed Fontan operation who underwent heart trans-
plantation and developed VS and reported a successful recov-
ery [31]. Taylor and Holtby reported a child with vasoplegia
who received 2 doses of MB at 2 mg/kg intravenously for
hypotension in relation to bypass and recovered from VS
[32]. Lee and Ing also reported the successful use of MB in a
7 years old child with dilated cardiomyopathy supported by
a left ventricular assisted device (VAD), a pulsatile extracorpo-
real device, and preoperatively anticoagulated with warfarin
presented for orthotopic heart transplant. The course was
complicated by persistent bleeding treated with prothrombin
complex concentrate and refractory post bypass vasoplegia
treated with methylene blue [33].
Although this is the first prospective comparative
controlled randomized study that used a single dose of MB
The management of vasoplegic syndrome in pediatric patients 275comparing it to norepinephrine in VS in children, it did not
follow the need of patients for a repeated dose and it did not
include all pathological types of congenital heart diseases.
In conclusion, MB showed superior efficacy and safety in
managing VS in pediatrics following CPB compared to nore-
pinephrine. The present study is still a step toward establishing
MB as a commonly used drug in VS even if it is not the first
choice. More studies are needed to compare it to other com-
monly used drugs as vasopressin.
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